← Back to Search

Diffusion-weighted imaging magnetic resonance imaging for Squamous Cell Carcinoma

N/A

Waitlist Available

Led By Gloria J Guzman Pérez-Carrillo, M.D.

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2-3 weeks post-standard of care treatment

Awards & highlights

Study Summary

This trial will use a new imaging technique to more accurately detect cancer recurrence and early non-responders to therapy in patients with squamous cell carcinoma of the neck.

Eligible Conditions

Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2-3 weeks post-standard of care treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2-3 weeks post-standard of care treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-3 weeks post-standard of care treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Apparent diffusion coefficient lowest value in a tumor (ADCmin)

Apparent diffusion coefficient mean (ADCmean)

Secondary outcome measures

Number of non-responders to treatment as measured by DWI MRI as compared to the number of non-responders to treatment as measured by FDG PET/CT

Trial Design

1Treatment groups

Experimental Treatment

Group I: DWI MRIExperimental Treatment1 Intervention

-The patients will undergo an optimized research neck DWI MRI, up to 3 weeks post-treatment and then a standard-of-care 3-month post-treatment FDG PET/CT examination.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor

1,931 Previous Clinical Trials

2,299,701 Total Patients Enrolled

Gloria J Guzman Pérez-Carrillo, M.D.Principal InvestigatorWashington University School of Medicine

Media Library

Diffusion-weighted imaging magnetic resonance imaging Clinical Trial Eligibility Overview. Trial Name: NCT04685798 — N/A

Squamous Cell Carcinoma Research Study Groups: DWI MRI

Squamous Cell Carcinoma Clinical Trial 2023: Diffusion-weighted imaging magnetic resonance imaging Highlights & Side Effects. Trial Name: NCT04685798 — N/A

Diffusion-weighted imaging magnetic resonance imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT04685798 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the capacity of this investigation in terms of participants?

"Accurate. The information on clinicaltrials.gov reveals that this research endeavour, which was first announced on September 2nd 2020, is presently enrolling participants. 60 individuals need to be enrolled at a single site in order for the study to reach completion."

Answered by AI

Are recruitment efforts underway for this trial?

"Affirmative. Clinicaltrials.gov verifies that this clinical trial, which was first made available on September 2nd 2020, is currently recruiting participants. Up to 60 patients must be enrolled from one research facility for the study to move forward."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT

2020. "Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04685798.